Appetite-suppressant drugs and heart valve abnormalities;Atteintes valvulaires des anorexigenes

Archives des Maladies du Coeur et des Vaisseaux

Volumn 92, Issue 9, 1999, Pages 1213-1219

  Adams, C ^a   Cohen, A ^b  

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^b HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; FENFLURAMINE; PHENTERMINE; SEROTONIN AGONIST; SEROTONIN RECEPTOR AFFECTING AGENT;

CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; PULMONARY HYPERTENSION; REVIEW; RISK ASSESSMENT; VALVULAR HEART DISEASE; ADULT; AGED; AORTA VALVE REGURGITATION; ARTICLE; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; MITRAL VALVE REGURGITATION; PULMONARY VALVE INSUFFICIENCY;

ADULT; AGED; AORTIC VALVE INSUFFICIENCY; APPETITE DEPRESSANTS; DEXFENFLURAMINE; FEMALE; FENFLURAMINE; HEART VALVE DISEASES; HUMANS; HYPERTENSION, PULMONARY; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; PHENTERMINE; PULMONARY VALVE INSUFFICIENCY; SEROTONIN AGENTS; SEROTONIN AGONISTS;

EID: 0032835560     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997 ; 337 : 581-8.
2. Pellikka PA, Tajik AJ, Khandheria BK et al. Carcinoid Heart Disease. Clinical and Echocardiographic Spectrum in 74 Patients. Circulation 1993 ; 87 : 1188-96.
3. Redfield MM, Nicholson WJ, Edwards WD, Tajik AJ. Valve Disease Associated with Ergot Alkaloid Use: Echocardiographic and Pathologic Correlations. Ann Intern Med 1992 ; 117 : 50-2.
4. Correspondence Valvular Heart Disease Associated with Fenfluramine-Phentermine. N Engl J Med 1997 ; 337 : 1772-6.
5. Kurz X, Van Ermen A. Correspondence. Valvular Heart Disease Associated with fenfluramine-phentermine. N Engl J Med 1997 ; 337 : 1772-3.
6. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine (abstract). N Engl J Med 1997 ; 337 : 635.
7. Cannistra LB, Cannistra AJ. Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment (abstract). N Engl J Med 1998 ; 339 : 771.
8. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations, novembre 1997. MMWR Morb Mortal Wkly Rep 1997 ; 46 : 1061-6.
9. Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med 1998 ; 339 : 719-24.
10. Weissman NJ, Tighe JF, Gottdiener JS, Gwynne JT, for the sustained-release dexfenfluramine study group. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med 1998 ; 339 : 725-32.
11. Khan MA, Herzog CA, St Peter JV et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med 1998 ; 339 : 713-8.
12. Burger AJ, Sherman HB, Charlamb MJ et al. Low incidence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months (abstract). Circulation 1998 ; 98 (suppl. 1) : 1-644.
13. Orlandi QG, Price D, Istfan N et al. Valvular abnormalities in asymptomatic obese individuals receiving fenfluramine, dexfenfluramine, or phentermine: a consecutive series (abstract). Circulation 1998 ; 98 (suppl. 1) : 1-645.
14. Bach DS, Rissanen AM, Pekkarinen TA, Armstrong WF. Absence of cardiac valve dysfunction among obese patients treated with Sibutramine (abstract). Circulation 1998 ; 98 (suppl. 1) : 1-645.
15. Keen WD, Permanente K, O'Boyle MK. Phentermine-Fenfluramine valvulopathy is uncommon (abstract). Circulation 1998 ; 98 (suppl. 1) : 1-6451.
16. Lopez-Jimenez F, Aldrich HR, Kumar V et al. Fen-phen use is not associated with an increased prevalence of significant valvular heart disease (abstract). Circulation 1998 ; 98 (suppl. 1) : 1-645.
17. Khan MA, Herzog CA, St Peter JV et al. The prevalence of cardiac valvular disease in appetit suppressant treated individuals and matched unexposed control subjects (abstract). Circulation 1998 : 98 (suppl. 1) : 1-645.
18. Kancheria M, Salti H, Otting L, Bonow RO, Mehlman DJ. Prevalence of valvular regurgitation in patients exposed to anorectic agents (abstract). Circulation 1998 ; 98 (suppl. 1) : 1-645.
19. Gross SB, Lepor NE, Daley WL, Buchbinder NA, Hickey A, Samuels BA. Dose and duration of appetite-suppressant therapy Impacts incidence of valvular heart disease (abstract). Circulation 1998 ; 98 (suppl. 1) : 1-28.
20. Gardin JM. An echocardiac evaluation of patients exposed to anorexigens as compared to unexposed matched controls. Plenary Session XII Late Breaking Clinical Trials. Novembre 11, 1998, 71st Scientific Sessions American Heart Association.
21. Brenot F, Hervé Ph, Petitpretz P, Parent F, Duroux P, Simonneau G. Primary pulmonary hypertension and fenfluramine use. Br Heart J 1993 ; 70: 537-41.
22. Abenhaïm L, Moride Y, Brenot F et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 1996 ; 335 : 609-16.
23. Wee CC, Phillips RS, Aurigemma G et al. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med 1998 ; 129 : 870-4.
24. Choong CY, Abascal VM, Weyman J et al. Prevalence of valvular regurgitation by doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am Heart J 1989 ; 117 : 636-42.
25. Jobic Y, Slama M, Tribouilloy C et al. Doppler echocardiographic evaluation of valve regurgitation in healthy volunteers. Br Heart J 1992 ; 69 : 109-13.
26. Singh JP, Evans JC, Levy D et al. Prevalence of valvular regurgitation in a population-based cohort (abstract). Circulation 1997; 96 (suppl. 1) : 1-541.
27. Spitzer WO. Valvular Heart Disease Associated with Fenfluramine-Phentermine. N Engl J Med 1997 ; 337 : 1774.
28. Devereux RB. Appetite-suppressants and valvular heart disease. N Engl J Med 1998 ; 339 : 765-7.
29. Parisi AP. Diet-drug debate. Ann Int Med 1998 ; 129 : 903-5.
30. Guidelines For the Management of Patients with Valvular Heart Disease. Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998 ; 98 : 1949-84.
31. Agence du médicament. Avis aux professionnels de santé. Anorexigènes et atteintes cardiopulmonaires. Janvier 1998.
32. Fishman AP. Aminorex to fen-phen: an epidemic foretold. Circulation 1999 ; 99 : 156-61.